What is it about?
There has been no standard chemotherapy for recurrent of metastatic salivary gland cancer because of its rarity and complexity of pathological types. Moreover, there have been a few prospective clinical trials for these patients. Hence, we conducted a prospective phase II trial to investigate the efficacy and safety of docetaxel plus cisplatin for the patients with non-squamous cell carcinoma of the head and neck.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Docetaxel plus cisplatin is effective for this rare malignancy of non-squamous cell carcinoma of the head and neck including salivary gland cancer.
Perspectives
Docetaxel plus cisplatin is one of the treatment option for salivary gland cancer and further development with immunotherapy is warranted.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial, Medical Oncology, September 2021, Springer Science + Business Media,
DOI: 10.1007/s12032-021-01581-z.
You can read the full text:
Resources
Contributors
The following have contributed to this page
